Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High‐Fat Diet: Possible Role of the NLRP3 Inflammasome
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Molecular mechanisms driving transition from simple steatosis to nonalcoholic steatohepatitis (NASH), a critical step in the progression of nonalcoholic fatty liver disease (NAFLD) to cirrhosis, are poorly defined. This study aimed at investigating the role of the purinergic receptor 2X 7 (PR2X 7), through the NLRP3 inflammasome, in the development of NASH. To this end, mice knockout for the Pr2x 7 gene (Pr2x 7−/−) and coeval wild‐type (WT) mice were fed a high‐fat diet (HFD) or normal‐fat diet for 16 weeks. NAFLD grade and stage were lower in Pr2x 7−/− than WT mice, and only 1/7 Pr2x 7−/− animals showed evidence of NASH, as compared with 4/7 WT mice. Molecular markers of inflammation, oxidative stress, and fibrosis were markedly increased in WT‐HFD mice, whereas no or significantly reduced increments were detected in Pr2x 7−/− animals, which showed also decreased modulation of genes of lipid metabolism. Deletion of Pr2x 7 gene was associated with blunted or abolished activation of NLRP3 inflammasome and expression of its components, which were induced in liver sinusoidal endothelial cells challenged with appropriate stimuli. These data show that Pr2x 7 gene deletion protects mice from HFD‐induced NASH, possibly through blunted activation of NLRP3 inflammasome, suggesting that PR2X 7 and NLRP3 may represent novel therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110 · cited 2×
“Treatment with the NLRP3 inflammasome blocker MCC950 attenuated liver inflammation and fibrosis in two mouse models of NASH, that is, the Alms1 mutant (foz/foz) mice fed with an atherogenic diet and C57BL/6 mice fed with an MCD diet [17].”
ResultNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“When flux of free fatty acids (FFAs) from diet, adipose tissue lipolysis, and hepatic de novo lipogenesis is higher than the rate of FFA oxidation or incorporation into triglycerides for storage as lipid droplets or export as VLDL, exceeding FFAs can generate lipotoxic intermediates which may induce oxidative stress,…”
BackgroundNguyen, M. T. A., Favelyukis, S., Nguyen, A.-K., Reichart, D., Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G., & Olefsky, J. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706762200 · Cited by 1,035
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645 · cited 1×
“These signals include glucose [33], saturated FFAs such as palmitate [34], the lipotoxic FFA metabolite ceramide [35], and modified lipoproteins such as oxidized LDLs, which may also act via formation of cholesterol crystals [36].”
BackgroundNLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486 · cited 3×
“This interpretation is consistent with previous observations showing that Nlrp3 gene deletion [18] or NLRP3 blockade [17] attenuates hepatic inflammation and fibrosis in animal models of NASH, and also with the evidence that these strategies are effective in attenuating other experimentally induced liver diseases [14].”
BackgroundResultNLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice
Wree, A., McGeough, M. D., Inzaugarat, M. E., Eguchi, A., Schuster, S., Johnson, C. D., Peña, C. A., Geisler, L. J., Papouchado, B. G., Hoffman, H. M., et al. (2018) · Hepatology · doi:10.1002/hep.29523 · Cited by 266
Fuchs, M., & Sanyal, A. J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.019 · Cited by 97 · cited 1×
“When flux of free fatty acids (FFAs) from diet, adipose tissue lipolysis, and hepatic de novo lipogenesis is higher than the rate of FFA oxidation or incorporation into triglycerides for storage as lipid droplets or export as VLDL, exceeding FFAs can generate lipotoxic intermediates which may induce oxidative stress,…”
Background
Cited by
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
Role of the Inflammasome in Liver Disease
de Carvalho Ribeiro, M., & Szabo, G. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032521-102529 · Cited by 277
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Ambrus-Aikelin, G., Takeda, K., Joetham, A., Lazic, M., Povero, D., Santini, A. M., Pranadinata, R., Johnson, C. D., McGeough, M. D., Beasley, F. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39805-z · Cited by 28
Zhang, L., Li, H.-L., Zhang, D.-D., & Cui, X.-C. (2021) · Human & Experimental Toxicology · doi:10.1177/09603271211002886 · Cited by 10
“Therefore, HFD was fed to WT mice and MRTF-A knockout mice for 16 weeks to establish NASH models.(16) then the following experiments were performed, including Hematoxylin and Eosin (HE) staining, Oil Red O staining, Sirius Red staining, immunohistochemical staining, quantitative reverse transcription-polymerase chain…”
Method
Metadata
- Authors
- Blasetti Fantauzzi, C., Menini, S., Iacobini, C., Rossi, C., Santini, E., Solini, A., & Pugliese, G.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2017-01
- Volume
- 2017
- Issue
- 1
- Pages
- 8962458-8962458
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2768610925
- Cited by
- 36
- References
- 8
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.